The AmoyDx® Comprehensive Panel is a next-generation sequencing-based test capable of detecting a wide range of alterations.
Tumor microsatellite instability (MSI) or mismatch repair (MMR) status serves as a predictive pan-cancer marker for response to immune checkpoint inhibitor therapy. NGS-based MSI testing across various cancer types offers both flexibility and accuracy, facilitating the incorporation of MSI status into decision-making processes and prediction of immune checkpoint blockade therapy efficacy.
Genetic polymorphisms in genes encoding bolizing enzymes and drug transporters can impact drug efficacy and toxicity. Identifying these genetic variations can help identify individuals predisposed to a high risk of toxicity and low response to standard doses of anti-cancer drugs.
Mutations in the BRCA1 and BRCA2 genes confer genetic predisposition to breast and ovarian cancers. The AmoyDx® Comprehensive Panel also detects BRCA1/2 mutations, allowing for the identification of candidates suitable for PARP inhibitor therapy.
Mutations( Hover over each mutational type to highlight genes covered )
All
AKT1
AKT1
SNV/INDELS
AKT2
AKT2
CNV
SNV/INDELS
AKT3
AKT3
CNV
SNV/INDELS
ALK
ALK
FUSIONS
SNV/INDELS
APC
APC
SNV/INDELS
AR
AR
SNV/INDELS
ARAF
ARAF
SNV/INDELS
ARID1A
ARID1A
SNV/INDELS
ATM
ATM
SNV/INDELS
ATR
ATR
SNV/INDELS
AURKA
AURKA
CNV
SNV/INDELS
BAP1
BAP1
SNV/INDELS
BCL2L11
BCL2L11
SNV/INDELS
BRAF
BRAF
FUSIONS
SNV/INDELS
BRCA1
BRCA1
SNV/INDELS
BRCA2
BRCA2
SNV/INDELS
CCND1
CCND1
CNV
SNV/INDELS
CCNE1
CCNE1
CNV
SNV/INDELS
CD274
CD274
CNV
SNV/INDELS
CDK12
CDK12
SNV/INDELS
CDK4
CDK4
CNV
SNV/INDELS
CDK6
CDK6
CNV
SNV/INDELS
CDKN2A
CDKN2A
SNV/INDELS
CDKN2B
CDKN2B
SNV/INDELS
CREBBP
CREBBP
SNV/INDELS
CTNNB1
CTNNB1
SNV/INDELS
DDR2
DDR2
SNV/INDELS
EGFR
EGFR
CNV
SNV/INDELS
EIF1AX
EIF1AX
SNV/INDELS
EPAS1
EPAS1
CNV
SNV/INDELS
EPCAM
EPCAM
SNV/INDELS
ERBB2
ERBB2
CNV
SNV/INDELS
ERBB3
ERBB3
SNV/INDELS
ERBB4
ERBB4
SNV/INDELS
ESR1
ESR1
SNV/INDELS
ETS2
ETS2
SNV/INDELS
FANCA
FANCA
SNV/INDELS
FBXW7
FBXW7
SNV/INDELS
FGF19
FGF19
CNV
SNV/INDELS
FGF3
FGF3
CNV
SNV/INDELS
FGFR1
FGFR1
CNV
FUSIONS
SNV/INDELS
FGFR2
FGFR2
CNV
FUSIONS
SNV/INDELS
FGFR3
FGFR3
CNV
FUSIONS
SNV/INDELS
FGFR4
FGFR4
SNV/INDELS
FLCN
FLCN
SNV/INDELS
FLT3
FLT3
SNV/INDELS
GNAS
GNAS
SNV/INDELS
HIF1A
HIF1A
CNV
SNV/INDELS
HRAS
HRAS
SNV/INDELS
IDH1
IDH1
SNV/INDELS
IDH2
IDH2
SNV/INDELS
IGF1R
IGF1R
CNV
SNV/INDELS
JAK1
JAK1
SNV/INDELS
JAK2
JAK2
SNV/INDELS
JAK3
JAK3
SNV/INDELS
KDM5C
KDM5C
SNV/INDELS
KDR
KDR
SNV/INDELS
KIT
KIT
SNV/INDELS
KRAS
KRAS
SNV/INDELS
MAP2K1
MAP2K1
SNV/INDELS
MAPK1
MAPK1
CNV
SNV/INDELS
MET
MET
CNV
SNV/INDELS
MLH1
MLH1
SNV/INDELS
MRE11
MRE11
SNV/INDELS
MSH2
MSH2
SNV/INDELS
MSH6
MSH6
SNV/INDELS
MTOR
MTOR
SNV/INDELS
MYC
MYC
CNV
SNV/INDELS
NF1
NF1
SNV/INDELS
NF2
NF2
SNV/INDELS
NOTCH1
NOTCH1
SNV/INDELS
NRAS
NRAS
SNV/INDELS
NRG1
NRG1
FUSIONS
NTRK1
NTRK1
FUSIONS
SNV/INDELS
NTRK2
NTRK2
FUSIONS
SNV/INDELS
NTRK3
NTRK3
CNV
FUSIONS
SNV/INDELS
PALB2
PALB2
SNV/INDELS
PAX8
PAX8
FUSIONS
SNV/INDELS
PDCD1
PDCD1
SNV/INDELS
PDGFRA
PDGFRA
CNV
SNV/INDELS
PGR
PGR
CNV
SNV/INDELS
PIK3CA
PIK3CA
CNV
SNV/INDELS
PIK3R1
PIK3R1
SNV/INDELS
PMS2
PMS2
SNV/INDELS
POLD1
POLD1
SNV/INDELS
POLE
POLE
SNV/INDELS
PSMD4
PSMD4
CNV
SNV/INDELS
PTCH1
PTCH1
SNV/INDELS
PTEN
PTEN
SNV/INDELS
RAF1
RAF1
SNV/INDELS
RASA1
RASA1
SNV/INDELS
RASAL1
RASAL1
SNV/INDELS
RB1
RB1
SNV/INDELS
RET
RET
CNV
FUSIONS
SNV/INDELS
RICTOR
RICTOR
CNV
SNV/INDELS
RIT1
RIT1
SNV/INDELS
ROS1
ROS1
FUSIONS
SNV/INDELS
RSF1
RSF1
CNV
SNV/INDELS
SF3B1
SF3B1
SNV/INDELS
SMAD4
SMAD4
SNV/INDELS
SMARCA4
SMARCA4
SNV/INDELS
SMO
SMO
CNV
SNV/INDELS
STK11
STK11
SNV/INDELS
TERT
TERT
SNV/INDELS
TOP2A
TOP2A
CNV
SNV/INDELS
TP53
TP53
SNP
SNV/INDELS
TSC1
TSC1
SNV/INDELS
TSC2
TSC2
SNV/INDELS
TSHR
TSHR
SNV/INDELS
VHL
VHL
SNV/INDELS
ABCB1
ABCB1
SNP
C8orf34
C8orf34
SNP
CDA
CDA
SNP
CYP19A1
CYP19A1
SNP
CYP2D6
CYP2D6
SNP
DPYD
DPYD
SNP
DYNC2H1
DYNC2H1
SNP
ERCC1
ERCC1
SNP
GSTP1
GSTP1
SNP
MTHFR
MTHFR
SNP
MTRR
MTRR
SNP
SEMA3C
SEMA3C
SNP
SLC28A3
SLC28A3
SNP
SOD2
SOD2
SNP
UGT1A1
UGT1A1
SNP
UMPS
UMPS
SNP
XPC
XPC
SNP
XRCC1
XRCC1
SNP
Target 128 genes on tumor actionable variants
Detection of SNV, Indel, fusion, CNV
Fast turnaround time within
1 week
Automatic and secure data analysis
Specifications
Target regions
128 genes and MSI
Alterations detected
SNV, InDel, Fusion, CNV, SNP, MSI
CNV and MSI detection are for tissue sample only.
CNV and MSI detection are for tissue sample only.
Sample type
FFPE tumor tissue, liquid biopsy
DNA input
FFPE DNA: optimal 100 ng (minimum 50 ng)
Plasma cfDNA: optimal 30 ng (minimum 10 ng)
Plasma cfDNA: optimal 30 ng (minimum 10 ng)
Sequencer
Illumina NextSeq 500, NovaSeq 6000
TAT for library preparation
2 days (hands-on time: 4 hours )
TAT from sample to report
5 days
Inquiry